Anshul Maheshwari Sells 18,542 Shares of SiBone (NASDAQ:SIBN) Stock

December 20, 2025 by InsiderTrades.com

Key Points

CFO Anshul Maheshwari sold 18,542 shares on December 18 at an average price of $20.15 for about $373,621, trimming his stake roughly 9.1% to 185,231 shares — part of several insider sales over the past months.
Wall Street support is rising: multiple firms (Canaccord, Truist, Morgan Stanley, Needham) have raised price targets and issued Buy/Overweight ratings, lifting the average target to about $25 and helping push the stock toward its 52‑week high.
Si‑Bone beat recent quarterly estimates with EPS of ($0.11) vs. ($0.16) expected and revenue of $48.66M vs. $46.67M, but the company remains unprofitable with negative margins and a negative P/E while showing strong liquidity (current ratio ~7.97).

SiBone (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 18,542 shares of the business's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $20.15, for a total transaction of $373,621.30. Following the sale, the chief financial officer directly owned 185,231 shares in the company, valued at approximately $3,732,404.65. This represents a 9.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

4 Recent Earnings Winners Riding Fresh Momentum in May

Anshul Maheshwari also recently made the following trade(s):

On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The shares were sold at an average price of $20.00, for a total transaction of $2,000.00.
On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total value of $24,012.00.
On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The shares were sold at an average price of $17.43, for a total value of $60,307.80.
On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total value of $47,676.33.
On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The shares were sold at an average price of $14.20, for a total value of $47,016.20.

SiBone Stock Performance

SiBone stock opened at $20.38 on Friday. The stock has a fifty day moving average price of $17.42 and a 200 day moving average price of $16.88. SiBone has a 52 week low of $12.49 and a 52 week high of $20.80. The firm has a market capitalization of $884.29 million, a P/E ratio of -39.96 and a beta of 0.76. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million during the quarter, compared to analysts' expectations of $46.67 million. Equities research analysts anticipate that SiBone will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On SiBone

A number of large investors have recently added to or reduced their stakes in SIBN. Tudor Investment Corp ET AL lifted its holdings in SiBone by 0.8% in the 3rd quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company's stock worth $3,798,000 after buying an additional 1,968 shares in the last quarter. PharVision Advisers LLC purchased a new stake in shares of SiBone during the third quarter worth about $431,000. XTX Topco Ltd increased its position in shares of SiBone by 70.9% during the third quarter. XTX Topco Ltd now owns 33,870 shares of the company's stock worth $499,000 after acquiring an additional 14,053 shares during the last quarter. Virtus Advisers LLC lifted its stake in shares of SiBone by 174.3% in the third quarter. Virtus Advisers LLC now owns 11,333 shares of the company's stock worth $167,000 after acquiring an additional 7,201 shares in the last quarter. Finally, Quarry LP boosted its holdings in SiBone by 862.6% in the third quarter. Quarry LP now owns 4,861 shares of the company's stock valued at $72,000 after purchasing an additional 4,356 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about SiBone

Here are the key news stories impacting SiBone this week:

Positive Sentiment: Canaccord raised its price target on SIBN from $26 to $27 and maintained a Buy rating, signaling stronger upside expectations that support further upside for the shares. Read More.
Positive Sentiment: Truist increased its price target from $21 to $23 and kept a Buy rating, adding incremental broker support for the stock's near-term rally. Read More.
Positive Sentiment: Needham published a bullish forecast calling for strong price appreciation for SIBN, adding another institutional voice to the buy-side narrative. Read More.
Positive Sentiment: Market headlines reported SIBN trading up roughly 5.4% after analyst upgrades, reflecting immediate market reaction to the research updates and lifting momentum. Read More.
Negative Sentiment: CFO Anshul Maheshwari sold 18,542 shares at an average price of $20.15 (total ~$373,621); the filing shows his holding decreased about 9.1%. Insider selling can raise short-term concern about insider conviction, even if sales are for personal reasons. Read More.
Negative Sentiment: SVP Michael A. Pisetsky sold 19,600 shares at an average of $20.15 (total ~$394,940); his position fell ~7.8% after the trade. Multiple insider disposals the same day can amplify investor caution. Read More.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of SiBone from $26.00 to $27.00 and gave the company a "buy" rating in a report on Wednesday. Truist Financial lifted their target price on SiBone from $21.00 to $23.00 and gave the company a "buy" rating in a report on Thursday. Morgan Stanley upped their price target on SiBone from $20.00 to $23.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 2nd. Needham & Company LLC boosted their target price on SiBone from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of SiBone in a report on Monday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $25.00.

Get Our Latest Report on SIBN

About SiBone

(Get Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.